is classified as a progressive neurological disease that affects the functioning of the brain, ultimately leading to neuron loss. It is a neurodegenerative disease of the brain which leads to loss of memory and cognitive functions. Alzheimer’s treatment is a high risk, high reward market which has a huge revenue generating potential.
This report identifies the Alzheimer’s Drugs market
size in terms of value for the year 2014-2016, and forecast of the same for year 2021. It highlights potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Alzheimer’s Drugs market.
- This report has been divided based on drug type which includes NMDA Receptor Antagonist and Acetylcholinesterase Inhibitor.
- This report also includes Alzheimer’s Drugs market by Phases, which includes Phase-I, Phase-II, Phase-III and Others.
- This report has been further segmented into major regions, which includes detailed analysis of each region such as Americas, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). Country level markets for each of the regions are also analyzed and determined.
The major countries considered under the Americas region are Argentina, Brazil and the North American region. The major countries considered under the Asia-Pacific region are China, Japan, India, South Korea and others. The major countries considered under the European region are United Kingdom, France, Germany and others.
Globally demand for Alzheimer’s Drugs is expected to witness growth in the upcoming future due to growing prevalence of the neurological disorder in the geriatric population, increasing average life span of people and the aging population. The major factor restraining the substantial growth of Alzheimer’s Drugs is the lack of techniques for diagnosing or treating Alzheimer’s disease. The major factor challenging the substantial growth of Alzheimer’s Drugs is the difficulty involved in the early diagnosis of indication of Alzheimer’s disease. North America and Europe has the highest markets share by value in global Alzheimer’s Drugs market and Asia Pacific region is projected to have a significant growth during the forecast period.
This market research report includes in depth analysis of Alzheimer’s Drugs in each application and in the regional segment separately to provide in depth view of key insights and market scenario. Forecasts are also provided for all the market segments for the period 2016-2021. This report also includes detailed profiling of following the major players in the global Alzheimer’s Drugs market:
- Eli Lilly
- GE Healthcare
- Bayer Pharmaceuticals